Argenica Therapeutics Ltd
AGN
Company Profile
Business description
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
Contact
117 Broadway
Unit 4
NedlandsWA6009
AUST: +61 893293396
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,613.49 | 0.33 | -0.00% |
| DAX 40 | 26,161.13 | 159.82 | 0.61% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,891.89 | 34.19 | 0.31% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |